Welcome to our last newsletter of the year! 2016 has been very exciting and rewarding for COPE and I would like to use the occasion of this last 2016 newsletter edition to look back on our main achievements.
In February, COPE was represented at the British Transplant Society congress in Glasgow with a project booth as well as an e-poster allowing us to broaden our network and further increase visibility for our work. In March, the WP2 team completed patient recruitment in the liver trial leading to our most important milestone of the year, but WP2 has now also reached the 6-months follow-up period for its last patient in September and the team is busy with in-depth data analysis as we speak. The COPE Consortium then got together for the 4th Annual Meeting held in April and - as always - we have greatly appreciated our partners' and collaborators' valuable input culminating in a wonderful joint dinner at the Balliol College.
During the summer months, our liver trial presented its very exciting and important preliminary results of normothermic machine perfusion versus static cold storage in liver preservation at the American Transplant Congress in Boston (USA), The Transplant Society congress in Hong Kong (PRC) and the DCD conference in Barcelona (ES). All presentations were very well received and raised great interest in the transplant community. The summer months also brought along the official project extension approval confirming the new end date of June 2018 and COPE submitted its 2nd interim scientific and financial report to the EU Commission.
We furthermore saw our partnership grow and expand with Cardiff & Vale University (UK), the Royal Free Hospital (UK), Hammersmith Hospital (UK), UCL (BE) and Semmelweis University (HU) joining our POMP trial and we are delighted about these new collaborations. Our COPE partner Poitiers started the planned experimental work based on the revised protocols - we are excited to read up on the first findings. Finally, the end of 2016 sees us at 80% of recruitment target in the COMPARE trial and 45% of recruitment target in the POMP trial and we look forward to finishing inclusions in 2017.
These are very impressive achievements for one year and it was only possible thanks to all our partners', collaborators' and supporters' hard work and dedication. On behalf of the entire COPE Consortium, I would like to thank you for your ongoing commitment, your good ideas and your bountiful energy to bring our joint work forward. We truly appreciate your time and effort and wish you a wonderful festive season with your family and loved ones.
With best wishes,